Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFlowtech Fluid. Regulatory News (FLO)

Share Price Information for Flowtech Fluid. (FLO)

Share Price is delayed by 15 minutes
Get Live Data
63.00    1.00 (1.61%)
Bid:
60.20
Ask:
63.00
Spread: 2.80 (4.651%)
Market Cap: £51.30m
FLO Live PriceLast checked at - London Stock Exchange

Intraday Flowtech Fluid. Share Chart

Acquisition

29 Apr 2005 07:00

Flomerics Group PLC29 April 2005 29 April 2005 Flomerics Group plc ("the Company") Acquisition of Microelectronics Research & Development Limited Flomerics Group plc ("Flomerics" or "the Company"), supplier of virtualprototyping analysis software for the electronics industries announces theacquisition of the entire share capital of Microelectronics Research &Development Limited ("MicReD") for a maximum total consideration ofapproximately €2.1 million. Initial consideration is approximately €898,000, ofwhich €653,000 is payable in cash, the remaining €245,000 is satisfied by theissue of 250,663 Ordinary Shares of 1 pence each in the Company ("OrdinaryShares"), 80% now and 20% after 1 year. The deferred consideration is dependenton the financial performance of MicReD in 2005 and 2006. MicReD is a Hungarian based company and was formed in 1997 as a spin-off fromBudapest University of Technology. MicReD employs 13 people all located inBudapest and is led by the Chief Executive Officer, Marta Rencz. The managementteam of MicReD will all remain with the business. Its primary product is theT3Ster (pronounced Trister) - instrumentation and software used for measuringthe thermal performance of chip packages. Existing customers include Philips,Infineon, ST Microelectronics, Intel, Samsung and IBM. In the year to 31December 2004 MicReD had audited income of approximately €538,000 and made aprofit before tax of €288,000. In the previous year the unaudited turnover wasapproximately €123,000. The net assets at 31 December 2004 were €234,000. The semiconductor companies that make up the main target market for the T3Sterrepresent a significant, and strategically important, sector of the Flomerics'customer base. The use of the T3Ster enables them to evaluate and improve thethermal performance of chip-package designs - often alongside the complementaryuse of Flomerics' thermal analysis software. Just as the need for Flomerics'products is driven by the increasing miniaturisation and thermal densities ofelectronics devices - so exactly the same trends are driving the need for theT3Ster. The acquisition is thus strongly synergistic with Flomerics' current corebusiness, and represents a significant step for Flomerics towards providing acomplete thermal-design solution for its customers. In order to satisfy part of the initial consideration application has been madefor 200,530 new ordinary shares of 1p each to be admitted to trading on AIM witheffect from 5 May 2005. Following admission the issued share capital of theCompany will be 14,847,110 Ordinary Shares of 1p each. Commenting on the transaction David Tatchell, Flomerics' Chief Executive said "This is an important first step in delivering on our strategy of growing theCompany by acquisition in a way that complements our organic growth plans. I amdelighted to welcome into the Group the world-leading expertise that the MicReDteam bring. The T3Ster has many applications in markets where Flomerics is wellestablished, and we believe therefore that there is great potential to expandthe business." Marta Rencz said "We are very excited to be a part of the Flomerics group.Flomerics is the acknowledged standard setter in this field and theirinfrastructure will enable us to maximise the potential of our products." For further information please contact: David Tatchell Chief Executive 020 8487 3000Chris Ogle Finance Director & Company Secretary Buchanan Communications 020 7466 5000Tim Thompson / Nicola Cronk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
20th May 20247:00 amRNSExercise of Options and Total Voting Rights
17th May 20242:54 pmRNSNotice of AGM
9th May 20247:00 amRNSAnnual Financial Report
1st May 20247:00 amRNSHolding(s) in Company
18th Apr 20244:10 pmRNSDirector/PDMR Shareholding
27th Mar 20242:28 pmRNSClarification note regarding Dividend - REPLACE
26th Mar 20247:16 amRNS2023 Annual Unaudited Results
25th Mar 202411:44 amRNSNotice of Results
1st Feb 202410:38 amRNSDirector/PDMR Shareholding
30th Jan 20247:00 amRNSTrading update
19th Dec 20237:00 amRNSHolding(s) in Company
25th Oct 202311:42 amRNSHolding(s) in Company
31st Aug 20234:25 pmRNSBoard Update
31st Aug 20237:00 amRNSPDMRs - Director Dealings
30th Aug 20237:00 amRNS2023 Half-year report
31st Jul 20237:00 amRNSTrading update & Notice of Half-year results
13th Jun 20231:42 pmRNSResult of AGM
5th Jun 20237:00 amRNSAwards under Long-Term Incentive Plan
5th Jun 20237:00 amRNSBoard update
19th May 20237:00 amRNSAvailability of Documents & Notice of 2023 AGM
15th May 20237:00 amRNSDirector Dealing
26th Apr 20237:01 amRNSAudited Annual Financial Report FY2022
12th Apr 20237:00 amRNSDirectorate Change
12th Apr 20237:00 amRNSUnaudited Preliminary Results-year ended 31.12.22
24th Mar 20237:00 amRNSNotice of Results - revised date
9th Mar 20238:00 amRNSAnnual Results and Presentation via IMC Platform
26th Jan 20237:00 amRNSTrading Update and Notice of Results
11th Jan 20237:00 amRNSBoard changes: NED Appointment & NED Retirement
21st Dec 20224:39 pmRNSHolding(s) in Company
31st Aug 20227:00 amRNSHalf-year Report - six months ended 30 June 2022
8th Aug 20226:27 pmRNSHolding(s) in Company
4th Aug 20227:30 amRNS2022 Half-Year Results - Investor Presentation
1st Aug 20227:00 amRNSGroup Trading Update & Notice of HY1 2022 results
21st Jul 20221:03 pmRNSHolding(s) in Company
1st Jun 20222:23 pmRNSResult of AGM and Total Voting Rights
18th May 20227:00 amRNSDirector/PDMR Shareholding
5th May 20222:20 pmRNS2021 Annual Report & Notice of 2022 AGM
3rd May 20227:00 amRNSGrant of Options under Long-Term Incentive Plan
30th Mar 20221:21 pmRNSDirector/PDMR Shareholding
29th Mar 20227:00 amRNSFY2021 Results & publication of the Annual Report
25th Mar 20225:36 pmRNSHolding(s) in Company
7th Mar 20229:00 amRNSNotice of Results and Investor Presentation
21st Feb 20225:49 pmRNSHolding(s) in Company
26th Jan 20227:01 amRNSTrading Statement
26th Jan 20227:00 amRNSAppointment of Nominated Adviser and Sole Broker
20th Jan 20224:41 pmRNSSecond Price Monitoring Extn
20th Jan 20224:36 pmRNSPrice Monitoring Extension
20th Dec 202112:58 pmRNSHolding(s) in Company
10th Dec 20214:41 pmRNSSecond Price Monitoring Extn
10th Dec 20214:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.